Duker indicated that EyePoint expects to report top line data for the Phase III LUGANO trial in mid-2026 with LUCIA data to follow closely, complete enrollment in the pivotal Phase III DME program in ...
Eyepoint Pharmaceuticals (NASDAQ:EYPT) outlined late-stage clinical progress for its lead retinal candidate DURAVYU and ...
Thank you, and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals, Inc.'s Fourth Quarter and Full Year 2025 financial results and recent corporate developments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results